Compare Amphastar Pharmaceuticals Inc (AMPH) vs Orion Office REIT Inc (ONL) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

ONL trades at $2.75, down 1.08% on the day, with a neutral technical signal and bearish moving averages. The company reported a net loss of $139.31 million in 2025, with revenue declining to $147.65 million. Despite negative profitability, the stock trades at a low price-to-book ratio of 0.26 and recently announced a $0.02 dividend. Strategic reviews and portfolio repositioning are ongoing, as noted in recent earnings calls (Business Wire, 2026-05-07).

Outlook remains challenged by persistent losses and high debt, but strategic asset sales and refinancing improvements offer potential stabilization. Risks include further revenue declines and office sector headwinds, while analyst sentiment is evenly split between buy and hold ratings.